Compared to small-molecule therapies, the nature of CAR-T/TCR therapies is such that they can be diversified with lower probability of failure in the clinic. Many companies and academic entities are … Read More
Improving Management of Gene and Cell Therapies
Pharmaceutical Executive, September 10, 2018Michael Ciarametaro, Mark Trusheim, Daniel S. Mytelka, Gregory L. Warren, and Donald Han After decades of anticipation, 2017 saw the approval of the first of a … Read More
- Page 2 of 2
- 1
- 2